ArticlePreventive medicine reports2025
Point-of-care testing of cardiovascular risk factors in Viennese community pharmacies: A cross-sectional study.
Article in Preventive medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Despite being the leading contributor to global mortality, cardiovascular diseases remain undetected in many individuals at-risk. The aim of this study was to evaluate the proportion of individuals with unrecognised cardiovascular risk factors among all-comers in community pharmacies. Methods: This cross-sectional study conducted in 47 Viennese community pharmacies between November 1, and December 31, 2024, screened adults for cardiovascular risk factors using point-of-care testing (HbA1c, lipid profile) and the age-appropriate Systematic Coronary Risk Evaluation 2. An optional follow-up after three months assessed whether medical referral occurred and pharmacotherapy was initiated or changed. Patients treated for diabetes or hyperlipidaemia were excluded. Results: Among 445 individuals, 51 % were identified with increased cardiovascular risk factors. Of these, 151 agreed to participate in the follow-up, in which 66 % were successfully contacted. The respondents reported an attendance rate of 57 % and 43 % received new or modified pharmacotherapy. Conclusions: Community pharmacy-based screening proved effective, identifying numerous previously undiagnosed individuals with increased cardiovascular risk, which is especially remarkable within a comprehensive healthcare system. However, follow-up rates remained low, indicating a gap between risk detection and medical action. A stronger integration of screening interventions with primary care and follow-up pathways with medical institutions may enhance the effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.